File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapeutic interventions to urologic chronic pelvic pain syndrome and UPOINT system for clinical phenotyping: How far are we?

TitleTherapeutic interventions to urologic chronic pelvic pain syndrome and UPOINT system for clinical phenotyping: How far are we?
Authors
Issue Date2022
PublisherSAGE.
Citation
Urologia Journal, 2022 How to Cite?
AbstractThe assessment and management of urologic chronic pelvic pain syndrome (UCPPS), is controversial. It is classified by voiding symptoms, pelvic pain, and bladder pain, which is weekly treated, weekly understood, and bothersome. In the aspect of clinical efforts and research to help people with this syndrome have been hampered by the deficiency of a widely reliable, accepted, and a valuable tool to evaluate the patient symptoms and quality of life (QoL) impact. However, the etiology comes into sight is multifactorial, and available treatment options have been imprecise considerably in present years. We compiled the published literature on the assessment of the syndrome, a tentative role of pharmacological and non-pharmacological (conservative, alternative, and invasive therapy) interventions in eradicating the disease as well as improving symptoms. The previously published literature on animal models has established the association of immune systems in the etiology, pathogenesis, and progression of the disease. The UPOINT system for clinical phenotyping of UCPPS patients has six predefined domains that direct multimodal therapy, which would lead to significant symptom improvement in the medical field. The narrative review aims to scrutinize the fluctuating scientist’s views on the evaluation of patient and multimodal treatment of the UPOINT system.
Persistent Identifierhttp://hdl.handle.net/10722/309882
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNaveed, M-
dc.contributor.authorChangXing, L-
dc.contributor.authorIhsan, AU-
dc.contributor.authorShumzaid, M-
dc.contributor.authorKamboh, AA-
dc.contributor.authorMirjat, AA-
dc.contributor.authorSaeed, M-
dc.contributor.authorBaig, MMFA-
dc.contributor.authorZubair, HM-
dc.contributor.authorNoreen, S-
dc.contributor.authorMadni, A-
dc.contributor.authorXiaohui, Z-
dc.date.accessioned2022-01-10T09:15:13Z-
dc.date.available2022-01-10T09:15:13Z-
dc.date.issued2022-
dc.identifier.citationUrologia Journal, 2022-
dc.identifier.urihttp://hdl.handle.net/10722/309882-
dc.description.abstractThe assessment and management of urologic chronic pelvic pain syndrome (UCPPS), is controversial. It is classified by voiding symptoms, pelvic pain, and bladder pain, which is weekly treated, weekly understood, and bothersome. In the aspect of clinical efforts and research to help people with this syndrome have been hampered by the deficiency of a widely reliable, accepted, and a valuable tool to evaluate the patient symptoms and quality of life (QoL) impact. However, the etiology comes into sight is multifactorial, and available treatment options have been imprecise considerably in present years. We compiled the published literature on the assessment of the syndrome, a tentative role of pharmacological and non-pharmacological (conservative, alternative, and invasive therapy) interventions in eradicating the disease as well as improving symptoms. The previously published literature on animal models has established the association of immune systems in the etiology, pathogenesis, and progression of the disease. The UPOINT system for clinical phenotyping of UCPPS patients has six predefined domains that direct multimodal therapy, which would lead to significant symptom improvement in the medical field. The narrative review aims to scrutinize the fluctuating scientist’s views on the evaluation of patient and multimodal treatment of the UPOINT system.-
dc.languageeng-
dc.publisherSAGE. -
dc.relation.ispartofUrologia Journal-
dc.titleTherapeutic interventions to urologic chronic pelvic pain syndrome and UPOINT system for clinical phenotyping: How far are we?-
dc.typeArticle-
dc.identifier.emailBaig, MMFA: faran@hku.hk-
dc.identifier.authorityBaig, MMFA=rp02755-
dc.identifier.doi10.1177/03915603211065301-
dc.identifier.hkuros331405-
dc.identifier.isiWOS:000739441700001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats